Iredell Memorial Hospital utilizes UV light to eliminate pathogens

In an effort to keep hospital rooms safe from drug-resistant organism for providers, patients and their families, Iredell Health System has implemented ultraviolet (UV) technology to better detect those pathogens.

"Patient safety is a top priority at Iredell," said Pam Gill, Director of Infection Prevention for Iredell Health System. "We chose to purchase these UV devices as an added measure to help us prevent healthcare-associated infections and ensure the safest possible environment of care for our patients, staff and visitors. The device is able to treat areas that are difficult to clean manually, and it allows us to track which rooms have been treated for more accurate reporting."

In addition to environmental services cleaning and disinfection hospital rooms with chemical cleaners, Iredell has implemented two Clorox Healthcare Optimum-UV Enlight Systems. These systems, which use UV light to kill organisms by inactivating their DNA in order to prevent them from replicating, are placed on either side of a patient bed and bathroom where they run for five minute intervals. This process further intensifies the cleaning process and removes microscopic organisms like MRSA and C. Diff in five minutes with an eight-foot range.

"With pathogens such as C. Diff. able to survive on surfaces for months at a time, we felt it was important to adopt a comprehensive approach – combining manual surface disinfection with UV technology," said Gill. "We want the adoption of the UV devices to give peace of mind to our patients, to reassure them their safety is what is most important to our staff."

Adding UV lights has been shown to reduce transmission of antibiotic-resistant bacteria by up to 30 percent, but the high cost of similiar UV machines--around $90,000--has turned off providers. 

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.